TMC435 was presented in four posters at the International Liver Congress™ 2010 by EASL, April 14-18, 2010

About TMC435 clinical trial programs TMC435 is a protease inhibitor jointly developed by Medivir and Tibotec to treat hepatitis C virus infections (HCV). TMC435 is currently being developed in three phase 2b clinical trials (C205, C206 and C215) in G1 treatment-naïve and in G1 patients that failed previous IFN-based treatment. C205 is a global phase 2b study initiated in May 2009 in approximately 400 genotype-1 treatment-naïve patients. It is a once daily treatment of TMC435 in doses of 75 mg and 150 mg given in addition to standard of care treatment, consisting of ribavirin and pegIFNalpha-2A. C206 is a global phase 2b study initiated in September 2009 in approximately 455 genotype-1 treatment-experienced patients. It is a once daily treatment of TMC435 in doses of 100 mg and 150 mg given in addition to standard of care treatment. C215 is a phase 2b study in Japan initiated in June 2009 in approximately 90 genotype-1 treatment-naïve patients. It is a once daily treatment of TMC435 in doses of 50 mg and 100 mg given in addition to standard of care treatment. During the International Liver Congress™ four posters on TMC435 were presented. The abstract titles are: 1. Combination of TMC435 with two novel NS5B inhibitors increases anti HCV activity and results in a higher genetic barrier in vitro 2. Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of TMC435 in Treatment-naive Hepatitis C (HCV)-infected patients in the OPERA-1 STUDY 3. Evaluation of Metabolic Interactions for TMC435 via Cytochrome P450 (CYP) Enzymes in Healthy Volunteers 4. Mathematical analysis of clinical data suggests that HCV genotype 1 has a high cellular infection rate that is reduced by Pegylated-Interferon alfa-2a/Ribavirin The posters are accessible on www.medivir.se / Investor relation / Latest events/ EASL For additional information, please contact Rein Piir, CFO & VP Investor Relations, Medivir +46 708 537 292.